<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512862</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-CCTO</org_study_id>
    <nct_id>NCT01512862</nct_id>
  </id_info>
  <brief_title>Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients</brief_title>
  <official_title>Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proteinuria is not only a marker of chronic kidney disease (CKD) progression, but also a
      marker of cardiovascular disease and death. In previous studies, active vitamin D deficiency
      is associated with cardiovascular risk factors such as albuminuria, diabetes mellitus, and
      lower glomerular filtration rate (GFR). And calcitriol was shown to have a preventive effect
      in progressive glomerular damage in a renal ablation model. Calcitriol, an active form of
      vitamin D (1,25-dihydroxyvitamin-D3), is commonly used for the treatment of secondary
      hyperparathyroidism in patients with advanced chronic kidney diseases.

      Therefore, the objective of this study is to evaluate the anti-proteinuric effect of
      calcitriol in non-diabetic kidney disease patients. They will be treated with calcitriol and
      placebo for 24 weeks and observed for 24 weeks after treatment. Proteinuria, renal function,
      serum and urinary inflammatory markers, and adverse event will be monitored.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in proteinuria</measure>
    <time_frame>6, 12 months after administration</time_frame>
    <description>Comparison of proteinuria amount checked by random urine protein/creatinine ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in renal function</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>Comparison of in serum creatinine level from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinary renal damage markers</measure>
    <time_frame>6, 12 months</time_frame>
    <description>Comparison of urinary TGF-beta, TNF-alpha, MCP-1 level from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months</description>
    <arm_group_label>Calcitriol</arm_group_label>
    <other_name>Calcio® (Hanmi Pharm Co., Korea)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nondiabetic kidney disease patients aged 19-70 years

          -  MDRD GFR ≥ 30 mL/min/1.73m2

          -  Patients with residual urine protein/creatinine ratio &gt; 200 mg/g

          -  Adequate blood pressure control as treated systolic blood pressure &lt;=140 or diastolic
             &lt;=90 mmHg with RAS inhibitor for more than 3 months

          -  Normotensive patients untreated with RAS inhibitors

          -  Serum intact PTH as 35-500 mg/dL and serum calcium less than 10.2 mg/dL

          -  Patients who have not been treated vitamin D within the 3 months prior to signing the
             informed consent form

        Exclusion Criteria:

          -  Patients with nephrotic-range proteinuria (24 hour urine protein &gt;3.5 g/24 hr)

          -  Patients with rapidly progressive glomerulonephritis

          -  Patients requiring renal replacement therapy immediately

          -  Hypercalcemia (uncorrected serum calcium level &gt; 10.2 mg/dL) within 3 months

          -  Malignant hypertension

          -  Heart failure (New York Heart Association [NYHA] functional class II to IV or LVEF
             less than 40%)

          -  Severe chronic obstructive lung disease

          -  Decompensated liver disease

          -  Known allergy or hypersensitivity to vitamin D

          -  Current treatment with steroids and/or immunosuppressive agents

          -  No other active primary malignancy requiring treatment or that limits survival to ≤ 2
             years

          -  History of noncompliance to medical regimen

          -  Inability to give an informed consent or to cooperate with researchers (e.g.,
             psychiatric disorder)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung Mi Oh, Pharm.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National Univerisy College of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yon Su Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nayoung Han, M.S.</last_name>
    <phone>+82-2-2072-0335</phone>
    <email>hans1217@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yon Su Kim, M.D., Ph.D.</last_name>
      <phone>82-2-2072-2264</phone>
      <email>yonsukim@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Dong Ki Kim, M.D., Ph.D.</last_name>
      <phone>82-2-2072-2303</phone>
      <email>dkkim73@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yon Su Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong Ki Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nayoung Han, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yon Su Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Calcitriol</keyword>
  <keyword>Off-label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

